Drug profile · INN
basiliximab
SIMULECT
basiliximab (SIMULECT) is a interleukin-2 receptor inhibitor. Route of administration: single-use. Current US regulatory status: approved.
Drug details — basiliximab
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- SINGLE-USE
- Patents
- 0
- Programs
- 4
- Data quality
- 0.84
Quick answer
basiliximab (SIMULECT) is a interleukin-2 receptor inhibitor. Route of administration: single-use. Current US regulatory status: approved.
Key facts
Mechanism of action
Interleukin-2 receptor inhibitor
Primary target: Interleukin-2 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Congress & event coverage
- PresentationPharma Manufacturing World
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is basiliximab?
basiliximab (SIMULECT) is a interleukin-2 receptor inhibitor. Route of administration: single-use. Current US regulatory status: approved.
What is the brand name for basiliximab?
SIMULECT is a marketed brand name for basiliximab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of basiliximab?
basiliximab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.